We congratulate Georgopoulos et al,1 for their excellent paper on intraocular inflammation with use of intravitreal bevacizumab (Avastin). Along with the efficacy, safety and tolerability is a key issue with the
Your doctor may use Avastin (bevacizumab) to treat wet age-related macular degeneration (AMD), diabetic eye disease or other eye problems. It is injected into the eye to help slow vision loss. These uses are considered “off-label” meaning your doctor might use Avastin for unapproved uses ...
Learn about Avastin® (bevacizumab) solution for IV infusion, including benefits, risks, possible side effects, patient support, and options for financial help. See full safety for more information.
SinceAvastin FDAapproval in 2004 forAvastin cancer treatment, the drug has also been used off-label for Avastin macular degeneration, administered by Avastin eye injection. Studies now show that Avastin or bevacizumab side effects outweigh the benefits of Avastin chemotherapy, particularly in Avastin br...
Initially approved for treatment of mCRC in the United States (US) and the European Union (EU) in 2004 and 2005, respectively, bevacizumab is now approved in a range of solid tumor indications (Fig. 1), and currently marketed in 134 countries worldwide. As one of the first therapies targ...
Recently, it has been reported that intravitreal injection of bevacizumab may be also useful for early vitreous hemorrhage in PDR in order to decrease the risk of new hemorrhages while clearing occurs and to minimize the indications of vitrectomy [15]. In addition, Chen and Park [27] and Avery...
strating safety and good results after off-label application of bevacizumab for corneal neovascularization. The purpose of this study was to investigate the effect of subconjunctival, perilimbal, and/or intrastromal bevacizu- mab on corneal NV in patients with penetrating keratoplasty (PKP). Mater...
We congratulate Georgopoulos et al, for their excellent paper on intraocular inflammation with use of intravitreal bevacizumab (Avastin). Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents, as ranibizumab (Lucentis) is now the standard of care for ...
Clinical, legal and ethical implications of the intraocular (off-label) use of bevacizumab (Avastin) - a South African perspective. S Afr Med J 2009; 99: 446-449 (this issue).Clinical,legal and ethical implications of theintra-ocular (o-label)use of bevacizumab (Avastin)–a South Afri-...